Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Next Previous
X
Search
Trial Profile

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NRTX-1001 (Primary)
  • Indications Partial epilepsies; Seizures; Temporal-lobe-epilepsy
  • Focus Adverse reactions; First in man
  • Sponsors Neurona Therapeutics

    • Most Recent Events

    • 06 Dec 2024 According to a Neurona Therapeutics media release, company announced positive clinical data from this trial which will be presented at the Annual Meeting of the American Epilepsy Society (AES), which is being held December 6-10, 2024, in Los Angeles, California.
    • 10 Sep 2024 According to a Neurona Therapeutics media release, company announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $3.8M grant to support the development of a next generation neural cell therapy candidate NRTX-1001 in view of the highly encouraging initial data from its ongoing Phase 1/2 clinical trial in adults with drug-resistant epilepsy.
    • 18 Jun 2024 According to a Neurona Therapeutics media release, company announced that the U.S Food and Drug Administration (FDA) has granted the company's lead product candidate, NRTX-1001,the RMAT expedited program designation for drug-resistant mesial temporal lobe epilepsy (MTLE).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top